Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Sorry, your browser doesn't support embedded videos.
Article content
Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra ® and Restylane ® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss 1
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months 1
Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs
Article content
Article content
ZUG, Switzerland — Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss. 1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months. 1 Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude. 2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance. 3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey.
Article content
'At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission.'
Article content
GALDERMA
Article content
In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss. 1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Article content
Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8. 1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment. 1 Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT: 1
The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 9 1
Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9: 1
85.7% of patients said their face looked less gaunt/sunken 1
88.6% said they 'loved' how the treatment maintained their facial structure 1
88.6% of patients said they 'loved' the regenerative effects of Sculptra treatment 1
88.6% felt they looked better than before the injection regimen 1
91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin 1
Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports. 1 'The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel.'
Article content
'These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care.'
Article content
MICHAEL SOMENEK, M.D.
Article content
WASHINGTON DC, UNITED STATES
Article content
Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report. 5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey. 6 * Restylane Contour is known as Restylane ® Volyme™ in countries outside of the U.S.
Article content
About the study
Article content
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.
Article content
1
Article content
Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.
Article content
1
Article content
About Galderma
Article content
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information:
Article content
Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.
Mansour MR, et al. The rise of 'Ozempic Face': Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321
Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online
Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. https://doi.org/10.1111/jocd.70094
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Article content
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Article content
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Article content
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
2 days ago
- Winnipeg Free Press
Smoke from Canadian wildfires brings unhealthy air to large swaths of the Midwest
Smoke from Canadian wildfires hovered over several Midwestern states Saturday, bringing warnings of unhealthy air for at least the third day. Air quality alerts were in effect in Iowa, Minnesota, Wisconsin and Michigan, as well as eastern Nebraska and parts of Indiana and Illinois. Forecasters said the smoky skies would remain for much of the day. People with lung disease, heart disease, children, older adults and pregnant women are most susceptible to the poor breathing conditions. Canadian environmental officials said smoke from forest fires that was causing reduced visibility and poor quality would persist into Sunday for some areas. The Switzerland-based air quality monitoring database IQAir, which assesses air quality in real time, listed the city of Minneapolis as having some of the worst air pollution in the world since Friday. The Air Quality Index (AQI) is expected to reach the red or unhealthy category in a large swath of Minnesota and will likely remain through Saturday. AQI is a system used to communicate how much air pollution is in the air. It breaks pollution down into six categories and colors, and advice on what isn't safe to do. They range from 'good' (the color green) to 'hazardous' (maroon). The smoke could start to decline beginning Saturday before spreading as far south as Tennessee and Missouri. The air could remain unhealthy for sensitive groups through Monday, state health officials said. The EPA's Air Quality Index converts all pollutant levels into a single number. The lower the number, the better. Anything below 50 is classified as 'healthy.' Fifty to 100 is 'moderate' while 100-150 is unhealthy for 'sensitive groups.' Anything above 150 is bad for everyone. Parts of Minnesota exceeded that number on Saturday. Health officials advise people with asthma and other lung disease, heart disease, children and older adults to avoid prolonged exposure to smoke and limit strenuous activities. They said to avoid burning things that could make the air pollution worse, and keep windows and doors closed to keep the smoke from getting inside. ___ The Associated Press receives support from the Walton Family Foundation for coverage of water and environmental policy. The AP is solely responsible for all content. For all of AP's environmental coverage, visit
CTV News
3 days ago
- CTV News
Trump administration weighs fate of $9M stockpile of contraceptives feared earmarked for destruction
Irene A Kerkulah, the health officer in charge at the Palala Clinic, looks at an almost-empty shelf at the clinic that once held contraceptives, in Bong County, Friday, June 13, 2025. (AP Photo/Annie Risemberg, File) BRUSSELS — President Donald Trump's administration says it is weighing what to do with family planning supplies stockpiled in Europe that campaigners and two U.S. senators are fighting to save from destruction. Concerns that the Trump administration plans to incinerate the stockpile have angered family planning advocates on both sides of the Atlantic. Campaigners say the supplies stored in a U.S.-funded warehouse in Geel, Belgium, include contraceptive pills, contraceptive implants and IUDs that could spare women in war zones and elsewhere the hardship of unwanted pregnancies. U.S. State Department deputy spokesman Tommy Pigott said Thursday in response to a question about the contraceptives that 'we're still in the process here in terms of determining the way forward.' 'When we have an update, we'll provide it,' he said. Belgium says it has been talking with U.S. diplomats about trying to spare the supplies from destruction, including possibly moving them out of the warehouse. Foreign Ministry spokesperson Florinda Baleci told The Associated Press that she couldn't comment further 'to avoid influencing the outcome of the discussions.' The Trump administration's dismantling of the U.S. Agency for International Development, which managed foreign aid programs, left the supplies' fate uncertain. Pigott didn't detail the types of contraceptives that make up the stockpile. He said some of the supplies, bought by the previous administration, could 'potentially be' drugs designed to induce abortions. Pigott didn't detail how that might impact Trump administration thinking about how to deal with the drugs or the entire stockpile. Costing more than US$9 million and funded by U.S taxpayers, the family planning supplies were intended for women in war zones, refugee camps and elsewhere, according to a bipartisan letter of protest to U.S. Secretary of State Marco Rubio from U.S. senators Jeanne Shaheen, a New Hampshire Democrat, and Alaska Republican Lisa Murkowski. They said destroying the stockpile 'would be a waste of U.S. taxpayer dollars as well as an abdication of U.S. global leadership in preventing unintended pregnancies, unsafe abortions and maternal deaths — key goals of U.S. foreign assistance.' They urged Rubio to allow another country or partner to distribute the contraceptives. Concerns voiced by European campaigners and lawmakers that the supplies could be transported to France for incineration have led to mounting pressure on government officials to intervene and save them. The executive branch of the European Union, through spokesman Guillaume Mercier, said Friday that 'we continue to monitor the situation closely to explore the most effective solutions.' The U.S. branch of family planning aid group MSI Reproductive Choices said it offered to purchase, repackage and distribute the stock at its own expense but 'these efforts were repeatedly rejected.' The group said the supplies included long-acting IUDs, contraceptive implants and pills, and that they have long shelf-lives, extending as far as 2031. Aid group Doctors Without Borders said incineration would be 'an intentionally reckless and harmful act against women and girls everywhere.' Charles Dallara, the grandson of a French former lawmaker who was a contraception pioneer in France, urged President Emmanuel Macron to not let France 'become an accomplice to this scandal.' 'Do not allow France to take part in the destruction of essential health tools for millions of women,' Dallara wrote in an appeal to the French leader. 'We have a moral and historical responsibility.' ___ Leicester reported from Paris. Matthew Lee contributed from Washington, D.C. Lorne Cook And John Leicester, The Associated Press
CTV News
3 days ago
- CTV News
Novo Nordisk shares extend losses, erasing nearly all gains since Wegovy launch
The weight-loss drug Wegovy is shown in this undated photo. THE CANADIAN PRESS/handout, Novo Nordisk Canada Inc. Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to wipe out almost all the gains made since the drugmaker launched its blockbuster weight-loss treatment Wegovy. The fall comes after U.S. President Donald Trump on Thursday sent letters to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. That prompted share price declines across the sector. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23 per cent on the day. Novo became Europe's most valuable listed company following the launch of Wegovy in June 2021. But its shares have plunged by more than two-thirds since peaking last year on concerns the drugmaker is losing ground in the obesity drug race. 'The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices,' Novo said in an emailed statement. Novo's shares were 4.9 per cent lower at 08:39 GMT. Friday's drop brings this week's losses to more than 30 per cent - the stock's worst-ever weekly fall. The European healthcare index .SXDP was down 1.6 per cent, its lowest since April. 'Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade,' said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly LLY.N and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. 'This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump,' Hansen said. (Reporting by Anna Pruchnicka, Elviira Luoma, Jacob Gronholt-Pedersen and Louise Breusch Rasmussen. Editing by Amanda Cooper and Mark Potter)
